The much-awaited Sai Parenteral’s IPO Day 1 kicked off on March 24, but the opening response has been modest so far. By early afternoon, the issue saw only limited traction, reflecting a cautious start from investors.
Let’s break it down in a simple, clear way — no noise, just what matters.
Market Performance: Sai Parenteral’s IPO Day 1 Subscription Update
On Sai Parenteral’s IPO Day 1, the numbers tell a slow but early-stage story.
- Total subscription: 2%
- Retail Individual Investors (RIIs): 2%
- Non-Institutional Investors (NIIs): 5%
- Qualified Institutional Buyers (QIBs): No bids yet
This kind of start isn’t unusual. IPOs often pick up pace in the later days as investors wait and watch.
Main News: IPO Opens with Defined Price Band and Investment Size
The IPO opened for subscription on March 24 and will remain open till March 27.
Here are the key financial details you should know:
- Price band: ₹372 to ₹392 per share
- Lot size: 38 shares
- Minimum investment: ₹14,896
At the upper price band, the company plans to raise ₹408.79 crore.
Breakup of Issue Size
- Fresh issue: 72.70 lakh shares (₹285 crore)
- Offer for Sale (OFS): 31.57 lakh shares (₹123.79 crore)
This structure shows a mix of fresh capital raising and stake dilution.
Company Details: What Sai Parenteral’s Does?
Sai Parenteral’s operates in the pharmaceutical space with a diversified product portfolio.
The company focuses on:
- Branded Generic Formulations
- CDMO (Contract Development and Manufacturing Organization) business
Its product range includes:
- Injectables
- Tablets
- Capsules
- Liquid orals
- Ointments
Among these, injectables stand out as a key segment, known for better margins compared to other categories. The company is gradually aiming to increase its contribution in the overall mix.
Where Will the IPO Money Be Used?
The funds raised from the IPO are planned to be used across multiple business areas:
- Capacity expansion and upgrading manufacturing facilities
- Setting up a new R&D Centre
- Repayment or prepayment of borrowings
- Meeting working capital needs
- Investment in subsidiary Sai Parenterals Pte Limited (Singapore)
- Supporting acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
- General corporate purposes
This clearly shows a focus on both expansion and strengthening existing operations.
IPO Timeline to Watch
Here are the important dates for Sai Parenteral’s IPO Day 1 investors:
- IPO Opening Date: March 24
- IPO Closing Date: March 27
- Allotment Date (Expected): March 30
- Listing Date (Tentative): April 2
Issue Management Details
- Book Running Lead Manager: Arihant Capital Markets Ltd.
- Registrar: Bigshare Services Pvt. Ltd.
These entities are responsible for managing and processing the IPO.
Summary: Sai Parenteral’s IPO Day 1 Snapshot
Sai Parenteral’s IPO Day 1 begins on a quieter note, with just 2% subscription so far. Early numbers suggest a wait-and-watch approach from investors.
The company operates in a broad pharmaceutical segment with a mix of products and a focus on injectables. The IPO is structured to raise over ₹408 crore, aimed at expansion, debt management, and business growth.
With a few days still left in the subscription window, the real momentum is yet to unfold.
